<DOC>
	<DOCNO>NCT02555748</DOCNO>
	<brief_summary>This pilot study open-label interventional study , prospective , non-comparative , sequential ( two stage ) , national , multicenter study . Patients start therapy sunitinib pazopanib standard first line treatment advance metastatic renal cell carcinoma enter study one two cohort ( 115 patient treat sunitinib 99 patient treated pazopanib ) . The purpose study examine feasibility sunitinib pazopanib dose individualisation base therapeutic drug monitoring ( TDM ) ass benefit approach term tolerance efficacy compare current empirical method base tolerance observation .</brief_summary>
	<brief_title>Therapeutic Drug Monitoring Sunitinib Pazopanib Advanced Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Patients start therapy sunitinib pazopanib standard first line treatment advance metastatic renal cell carcinoma . 2 . Measurable tumour define RECIST criterion version 1.1 . 3 . Age ≥ 18 year old . 4. WHO Performance Status ≤ 2 . 5 . Life expectancy ≥ 6 month . 6 . Adequate cardiac function ( baseline Left Ventricular Ejection Fraction ( LVEF ) ≥ 50 % determined Multiple Gated Acquisition scan ( MUGA ) echocardiography ) pulmonary function . 7 . Renal function define creatinine clearance ( Cockcroft Gault formula ) &gt; 30 mL/min . 8 . Adequate liver function define : total bilirubin ≤ 1.5 x Upper Limit Normal ( ULN ) ; Alanine AminoTansferase ( ALAT ) Aspartate AminoTransferase ( ASAT ) ≤ 2.5 x ULN ; Concomitant elevation bilirubin ASAT/ALAT 1.0 x ULN allow . 9 . Patients must provide write informed consent prior performance studyspecific procedures assessment , must willing comply treatment followup . 10 . Negative pregnancy test woman childbearing potential . 11 . Women childbearing potential must use adequate method contraception avoid pregnancy throughout study ( study entry 30 day last administration study treatment ) . 12 . Patients affiliate social health insurance . 1 . Patients without venous access blood sampling . 2 . Hypersensitivity active substance excipients . 3 . History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis . 4 . Corrected QT interval ( QTc ) &gt; 480msecs use Bazett 's formula . 5 . Patients treat anticoagulant treatment ( preventive curative ) . 6 . Patients concurrent severe and/or uncontrolled medical disease could compromise participation study , , limit : Uncontrolled infection . Cardiovascular condition within last 6 month cardiac angioplasty stenting , myocardial infarction , unstable angina , coronary artery bypass graft surgery , symptomatic peripheral vascular disease , Class III IV congestive heart failure , define NewYork Heart Association ( NYHA ) , clinically significant irregular heartbeat require medication . Poorly control hypertension [ define systolic blood pressure ≥140 mmHg diastolic pressure ≥90 mmHg ) . History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism deep venous thrombosis ( DVT ) within past 6 month . Note : patient recent DVT treat therapeutic anticoagulating agent least 6 week eligible . 7 . Evidence active bleeding bleed diathesis . 8 . Patients treat drug recognize strong inhibitor inducer isoenzyme cytochrome P450 isoenzyme 3A4 ( CYP3A4 ) within last 14 day prior inclusion and/or study . 9 . Patients already treated anticancer treatment previous four week patient require anticancer treatment study ( chemotherapy , immunotherapy , hormonotherapy , radiotherapy surgery ) . 10 . Pregnant breastfeed woman . 11 . Positive diagnostic HIV , B C hepatitis . 12 . Patients serious and/or unstable preexist medical , psychiatric , condition could interfere patient 's safety , provision inform consent , compliance study procedure . 13 . Patients forfeit his/her freedom administrative legal award guardianship .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>